Eli Lilly Says FDA To Convene In-person Meeting Of Peripheral & Central Nervous System Drugs Advisory Committee On June 10, To Discuss Donanemab
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announced that the FDA will hold an in-person meeting of the Peripheral & Central Nervous System Drugs Advisory Committee on June 10 to discuss Donanemab, as reported by Reuters.
May 07, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's upcoming FDA meeting on June 10 to discuss Donanemab could significantly impact investor sentiment and the company's stock price.
The FDA's decision to discuss Donanemab, a drug developed by Eli Lilly, indicates a critical step towards its potential approval. Positive outcomes from this meeting could lead to increased investor confidence and a rise in Eli Lilly's stock price due to the anticipation of new revenue streams from Donanemab. However, the actual impact will depend on the outcomes and feedback from the FDA meeting.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100